Robust and durable serological response following pediatric SARS-CoV-2 infection

Hanna Renk1, Alex Dulovic2, Alina Seidel3

  • 1University Children's Hospital Tübingen, Tübingen, Germany.

Nature Communications
|January 11, 2022
PubMed

Insights

Children exhibit a more robust and longer-lasting humoral immune response to SARS-CoV-2 infection than adults. This finding is crucial for developing pediatric COVID-19 vaccination strategies.

Area of Science:

  • Immunology
  • Virology
  • Pediatrics

Background:

  • The long-term humoral immune response in children post-SARS-CoV-2 infection is not well understood.
  • This knowledge gap impacts the development of pediatric COVID-19 vaccination programs.

Purpose of the Study:

  • To investigate the quality and persistence of humoral immunity in children and adults following SARS-CoV-2 infection.
  • To compare immune responses between pediatric and adult populations.

Main Methods:

  • Assessed serological responses at 3-4 and 11-12 months post-infection in 548 children and 717 adults from 328 households.
  • Utilized a multiplex immunoassay for 23 coronavirus antigens and three commercial SARS-CoV-2 antibody assays.
  • Analyzed neutralization activity against SARS-CoV-2 wild type and Delta variant using a pseudotyped virus assay.

Main Results:

  • Children were five times more likely to be asymptomatic compared to adults.
  • Children demonstrated higher specific antibody levels that persisted longer (96.2% vs. 82.9% seropositive at 11-12 months).
  • Symptomatic and asymptomatic infections induced similar humoral responses; neutralization was reduced against the Delta VOC in both groups.

Conclusions:

  • Children possess a more durable long-term humoral immune response to SARS-CoV-2 infection than adults, irrespective of infection severity.
  • Findings support the need for tailored pediatric SARS-CoV-2 vaccination strategies based on robust and sustained immune responses.